<DOC>
	<DOCNO>NCT00847535</DOCNO>
	<brief_summary>This clinical investigation approve US FDA Canadian Health Authority study safety potential effectiveness autologous muscle cell treatment stress urinary incontinence .</brief_summary>
	<brief_title>An Investigation Safety 4 Different Doses Autologous Muscle Derived Cells Therapy Stress Urinary Incontinence</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Stress</mesh_term>
	<criteria>Patient SUI normal detrusor activity confirm urodynamics Patient bladder capacity &gt; 200 mL Patient 's incontinence show improvement least 6 month Patient fail prior treatment ( e.g. , behavior modification , bladder exercise , biofeedback , electrical stimulation , bulk injection , urethral suspension and/or drug therapy ) Patient know vesicoureteral reflux , vaginal prolapse beyond introitus , significant pelvic floor abnormality high pressure instability Patient neuromuscular disorder ( e.g. , muscular dystrophy , multiple sclerosis ) Patient uncontrolled diabetes Patient pregnant , lactate , plan become pregnant course study Patient morbidly obese ( defined 100 pound ideal body weight , BMI â‰¥40 ) would expect benefit treatment Patient current acute condition involve cystitis urethritis Patient schedule receive radiation treatment vicinity Patients history radiation treatment urethra adjacent structure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>